To systematically evaluate the effect of Polygoni Cuspidati Rhizoma et Radix and its compounds and patent medicines on improving dyslipidemia.Methods:Databases including Chinese National Knowledge Infrastructure(CNKI)，China Science Periodical Database(CSPD)，Chinese Citation Database(CCD)，China Biology Medicine disc(CBMdisc)，PubMed，and Web of Science from 2000 to 2020 were retrieved，and randomized controlled trials(RCTs) related to Polygoni Cuspidati Rhizoma et Radix in the treatment of dyslipidemia were collected.Note express was used for literature management.According to inclusion and exclusion criteria，the papers were screened out.The data extraction table was used to extract materials and evaluate their quality.The included papers were analyzed by RevMan 5.1，and Meta-analysis was conducted on the results.Results:Fourteen RCTs were finally included，involving 1692 patients.The result showed that compared with the control group，Polygoni Cuspidati Rhizoma et Radix extract and its compound significantly decreased the levels of total cholesterol(TC)(MD=-0.46，95%CI=-0.67 to -0.24)，triglyceride(TG)(MD=-0.44，95%CI=-0.62 to -0.26)，high-density lipoprotein cholesterol(HLD-C)(MD=0.24，95%CI=0.11 to 0.37，P=0.000 3)，and low-density lipoprotein cholesterol(LDL-C)(MD=-0.41，95%CI=-0.77 to -0.06，P=0.02).Conclusion:Polygoni Cuspidati Rhizoma et Radix extract preparation and Chinese herbal compounds and marketed Chinese patent medicines with Polygoni Cuspidati Rhizoma et Radix as the main component have good efficacy and safety in improving dyslipidemia，which can provide references for further clinical medication.